2026-01-02 - Analysis Report
Okay, let's break down the analysis of TG Therapeutics Inc. (TGTX).

**1) Return Rate vs. S&P 500 (VOO)**

*   **Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 72.74%
*   **VOO (S&P 500) Cumulative Return:** 105.07%
*   **Divergence:** -32.33 (Relative Divergence: 15.5)

**Analysis:** TGTX has significantly underperformed the S&P 500.  The divergence indicates that TGTX's return is 32.33 percentage points lower than the S&P 500. The relative divergence of 15.5 suggests that the current underperformance is closer to the lower end of its historical fluctuation range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha    | Beta   | Cap(B) |
|------------|----------|----------|----------|--------|--------|
| 2016-2018  | -50.0%   | 71.3%    | -79.0%   | 1.8    | 0.7    |
| 2017-2019  | 131.0%   | 83.1%    | 90.0%    | 1.8    | 1.8    |
| 2018-2020  | 352.0%   | 83.1%    | 320.0%   | 1.6    | 8.3    |
| 2019-2021  | 363.0%   | 79.7%    | 287.0%   | 1.6    | 3.0    |
| 2020-2022  | -17.0%   | 94.7%    | -36.0%   | 1.9    | 1.9    |
| 2021-2023  | -65.0%   | 94.7%    | -93.0%   | 2.4    | 2.7    |
| 2022-2024  | 160.0%   | 83.7%    | 130.0%   | 2.3    | 4.8    |
| 2023-2025  | 96.0%   | 83.1%    | 28.0%   | 1.1    | 4.7    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Highly volatile, ranging from -65% to +363%. This highlights the stock's speculative nature and sensitivity to specific periods.
*   **MDD (Maximum Drawdown):** Consistently high MDD values (71.3% to 94.7%) indicate significant potential for losses.
*   **Alpha:** Alpha is also very volatile, demonstrating periods of substantial outperformance and underperformance compared to the benchmark. The high Alpha values during 2018-2021 indicate periods where TGTX significantly exceeded expected returns.
*   **Beta:** Beta values consistently above 1 (ranging from 1.1 to 2.4) mean the stock is more volatile than the overall market (S&P 500).  A Beta near 2 or higher suggests the stock tends to amplify market movements.
*   **Cap(B):** TGTX's market cap grew significantly in 2018-2020, then stabilized in the following years.

**2) Recent Stock Price Fluctuations**

*   **Close:** 29.81
*   **Last-market:** {'price': 29.81, 'previousClose': 29.75, 'change': 0.2}
*   **5-day SMA:** 30.386
*   **20-day SMA:** 30.849
*   **60-day SMA:** 32.3919

**Analysis:** The stock price is currently below all three Simple Moving Averages (SMA).  The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA. This *could* suggest a short-term downtrend. The slight increase of 0.2 between the previous close and price might reflect fluctuation issues (small rebound).

**3) RSI, PPO, Divergence, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 44.78 (Below 50, indicating slightly bearish momentum)
*   **PPO:** -0.189 (Slightly negative, suggesting the short-term moving average is slightly below the long-term moving average)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (31 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -0.8 (-): 단기하락 (Short-term decrease)
*   **Expected Return (%):** 0.0 (No expected excess return compared to S&P 500 long-term)

**Analysis:**

*   The MRI is high, which *suggests* a favorable investment opportunity, but must be viewed cautiously in light of the other indicators.
*   The RSI and PPO suggest a slight bearish sentiment in the short term.
*   The negative divergence change indicates a recent decline in performance relative to the S&P 500.
*   The 0% expected return is concerning, suggesting no anticipated outperformance compared to the S&P 500 in the long run.

**4) Recent News & Significant Events**

*   **Mixed Sentiment:** The news headlines present a mixed picture.
    *   Some articles highlight potentially attractive financial prospects and undervaluation.
    *   Others point to weaknesses and potential earnings caveats that led to price declines.
    *   Analyst recommendations suggest a "Moderate Buy."

**Analysis:**  The news indicates conflicting views on TGTX. While some sources see potential, others highlight risks and concerns. This underscores the uncertainty surrounding the stock.

**4-2) Analyst Opinions**
*   **Analyst Consensus:**
    - Key: None
    - Mean (1=StrongBuy~5=Sell): - (~-)
    - Opinions: 7
    - Target Price (avg/high/low): 44.29 / 60.00 / 13.00
*   **Recent Rating Changes:**
    - [0] : → ()
    - [1] : → ()
**Analysis:** The analyst opinions show that the average target price is significantly higher than the current price, which suggests the undervaluation of the stock.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출     |
|------------|------|----------|
| 2025-11-05 | 2.69 | 0.16 B$ |
| 2025-08-08 | 0.19 | 0.14 B$ |
| 2025-05-09 | 0.03 | 0.12 B$ |
| 2024-11-07 | 0.03 | 0.08 B$ |
| 2025-11-05 | 0.03 | 0.08 B$ |

**Analysis:**

*   **EPS (Earnings Per Share):** The EPS shows a drastic increase on 2025-11-05. The EPS has significantly increased compared to previous quarters.
*   **매출 (Revenue):** Revenue has generally been increasing over the past few quarters.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $0.16B    | 82.63%        |
| 2025-06-30   | $0.14B    | 86.58%        |
| 2025-03-31   | $0.12B    | 87.14%        |
| 2024-12-31   | $0.11B    | 85.77%        |
| 2024-09-30   | $0.08B    | 88.86%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30   | $0.61B    | 64.37% |
| 2025-06-30   | $0.28B    | 10.20% |
| 2025-03-31   | $0.24B    | 2.13%  |
| 2024-12-31   | $0.22B    | 10.49% |
| 2024-09-30   | $0.19B    | 2.02%  |

**Analysis:**

*   **Revenue:** Increasing revenue quarter-over-quarter suggests positive business momentum.
*   **Profit Margin:** Consistently high profit margins indicate efficient cost management and strong pricing power.
*   **Equity:** Equity has increased significantly, which is generally a positive sign.
*   **ROE (Return on Equity):** The ROE is very high in the most recent quarter.

**7) Comprehensive Analysis**

*   **Mixed Signals:** TGTX presents a mixed picture. While recent earnings show significant improvements and analysts have buy opinions, the stock has underperformed the S&P 500.
*   **High Volatility:** The stock exhibits high volatility, as demonstrated by the high Beta and MDD values.
*   **Risk Factors:** The negative divergence change and 0% expected return are concerning signs.
*   **Positive Developments:** On the other hand, revenue, profitability, and equity have been increasing in recent quarters.
*   **News & Analyst Sentiment:** The recent news articles and analyst ratings don't offer a clear consensus. Some analysts believe the stock is undervalued and the company has attractive financial prospects, while others point to potential risks and weaknesses.

**Conclusion:**

Investing in TGTX appears to be a high-risk, high-reward proposition. The company shows improving financial metrics, but its historical volatility and recent underperformance compared to the S&P 500 should not be ignored. The recommendation to invest requires careful consideration of one's risk tolerance and investment goals.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.